Hasbro, Inc. vs Invesco Ltd. — how do they compare? Hasbro, Inc. trades at $93.46 (market cap $13.05B), while Invesco Ltd. trades at $29.69 (market cap $13.28B). The key difference: Hasbro, Inc. and Invesco Ltd. are close in size by market cap, and Hasbro, Inc. pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Invesco Ltd. for 77 Days on average.
| HAS | IVZ | |
|---|---|---|
Market Cap | $13.05B | $13.28B |
Volume | 1,207,655 | 3,698,033 |
Sector | Consumer Cyclical | Financials |
52-Week High | $105.88 | $33.31 |
52-Week Low | $70.95 | $22.44 |
Typical Hold Time | 97 Days | 77 Days |
Enterprise Value | $15.24B | $23.45B |
Dividend Yield | 3.03% | 2.86% |
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals and key support at $90. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters, though 2025 showed a net loss of $322.4 million. Analyst consensus remains positive with a $107.60 price target and no sell ratings among 33 analysts.
Outlook remains constructive with projected 2026 revenue growth to $5.0B and net income of $794M, supported by Magic: The Gathering's strong performance. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The stock offers 18.5% upside to consensus target with institutional ownership showing mixed positioning.
Invesco (IVZ) trades at $30.50, up 0.39% on the day, with a mixed technical outlook showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $281.7 million for 2025 despite revenue growth to $6.38 billion, with profitability metrics like ROE at -2.97% indicating challenges. Recent news highlights the expansion of its QQQ ETF suite and a dividend declaration, while analyst consensus remains cautiously optimistic with a $33.71 price target.
The outlook for IVZ hinges on reversing negative earnings trends and capitalizing on ETF growth initiatives. Key opportunities include strong asset under management growth and product innovation, but risks persist from competitive pressures and market volatility. Investors should weigh the potential for operational improvement against ongoing profitability concerns.
Trailing returns across standard periods
Latest headlines on both assets
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →